A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone.

[1]  O. Hornykiewicz.  Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA). , 1973, British medical bulletin.

[2]  C. Marsden,et al.  Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase , 1973, Journal of neurology, neurosurgery, and psychiatry.

[3]  T. Chase,et al.  Methyldopahydrazine as an adjunct to L‐dopa therapy in parkinsonism , 1972, Neurology.

[4]  J. Reid,et al.  Action of L‐α‐methyldopahydrazine on the blood pressure of patients receiving levodopa , 1972, British Journal of Pharmacology.

[5]  H. Mars,et al.  Cannabis, nicotine and alcohol compared. , 1971 .

[6]  S. Ringel,et al.  Failure of vitamin B6 to reverse the l-dopa effect in patients on a dopa decarboxylase inhibitor , 1971, Journal of Neurology Neurosurgery & Psychiatry.

[7]  J. Reid,et al.  Idiopathic Parkinsonism Treated with an Extracerebral Decarboxylase Inhibitor in Combination with Levodopa , 1971, British medical journal.

[8]  L. Lasagna,et al.  METABOLISM AND ABSORPTION OF l‐3,4 DIHYDROXYPHENYLALANINE IN PATIENTS WITH PARKINSON'S DISEASE , 1971, Annals of the New York Academy of Sciences.

[9]  A. Barbeau.  Long-term side-effects of levodopa. , 1971, The Lancet.

[10]  D. Calne,et al.  The metabolism of orally administered l‐DOPA in Parkinsonism , 1969, British journal of pharmacology.

[11]  George C. Cotzias,et al.  Modification of Parkinsonism--chronic treatment with L-dopa. , 1969, The New England journal of medicine.